Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

76 results about "Degenerative change" patented technology

Degenerative changes in the spine are common and occur in most people, with varying degrees of severity. There are several contributing factors for these degenerative changes, but aging is the most common cause. As you get older, the discs of cartilage that provide support between the vertebrae tend to lose water and begin drying out.

Composition for treatment of cartilage disease

ActiveUS20100015102A1Improve lubrication functionImprove practicalityPowder deliveryBiocideDiseaseDegenerative change
The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue.
Owner:MOCHIDA PHARM CO LTD +1

Transcorporeal spinal decompression and repair systems and related methods

A system and method are provided for making an access channel through a vertebral body to access a site of neural compression, decompressing it, and repairing the channel to restore vertebral integrity. System elements include an implantable vertebral plate, a guidance device for orienting bone cutting tools and controlling the path of a cutting tool, a bone cutting tool to make a channel in the vertebral body, a tool for opening or partially-resecting the posterior longitudinal ligament of the spine, a tool for retrieving a herniated disc, an implantable device with osteogenic material to fill the access channel, and a retention device that lockably-engages the bone plate to retain it in position after insertion. System elements may be included in a surgery to decompress an individual nerve root, the spinal cord, or the cauda equina when compressed, for example, by any of a herniated disc, an osteophyte, a thickened ligament arising from degenerative changes within the spine, a hematoma, or a tumor.
Owner:GLOBUS MEDICAL INC

Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof

InactiveUS20080249038A1Prevent neurotoxic-stress induced apoptosisAvoid damageOrganic active ingredientsNervous disorderDiseaseDegenerative change
The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenerative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
Owner:QUARK FARMACUITIKALS INC

Rotary cervical curvature tractor

The invention relates to a rotary cervical curvature tractor. A supporting point is arranged at the rear part of the cervical vertebra of a human body and the traction is carried out along the curvature arc direction of the cervical vertebra of the human body. By the technical scheme, an active mechanical acting force is utilized to carry out curvature traction on the cervical vertebra, so that not only is the safety of the cervical vertebra ensured and new damage to the cervical vertebra cannot be caused, but also the cervical vertebra of a patient suffering from the cervical vertebra disease can be recovered to the normal and original physiological curvature; due to the adoption of the curvature traction, the intervertebral space can be widened and the stability and the normal physiological functions of the cervical vertebra can be recovered; the muscle spasm is relieved, adhered tissues are stripped and loosened and the inflammation is eliminated; and the blood supply is improved and the rotary cervical curvature tractor is beneficial for recovering the nervous tissue function and has a certain relieving and recovering effects on the degenerative change of the vertebral column of the human body, the neck pain and the cervical spondylotic radiculopathy which are caused by the case that the patient bends over a table to work, study and drive for a long time.
Owner:魏永强

Intervertebral disc degenerative change diagnosis and treatment marker

The invention discloses a gene TMED2 which can serve as a molecular marker for diagnosing the intervertebral disc degenerative change. Experiments prove that in comparison with a normal person, the expression quantity of the gene TMED2 in intervertebral disc degenerative change patients is large. The invention further discloses the gene TMED2 which can be used for preparing a drug for treating the intervertebral disc degenerative change. Apoptosis experiments prove that overexpression of the gene TMED2 can promote nucleus pulposus cell apoptosis. The research result provides a new intervertebral disc degenerative change clinic diagnosis method and provides a drug new target for treating the intervertebral disc degenerative change.
Owner:GUAN BOJIAN BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products